Atorvastatin inhibits myocardin expression in vascular smooth muscle cells

Hypertension

Volumn 60, Issue 1, 2012, Pages 145-153

  Li, Jingjing ^a   Jiang, Jixin ^a   Yin, Hao ^a   Wang, Lifeng ^a   Tian, Ruijuan ^a   Li, Haijie ^a   Wang, Zengyong ^a   Li, Dong ^a   Wang, Yuebing ^a   Gui, Yu ^c   Walsh, Michael P ^b   Zheng, Xi Long ^a,b  

^a NANKAI UNIVERSITY   (China)

^b Smooth Muscle Research Group   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Atorvastatin; Contraction; Myocardin; Rhoa ROCK pathway; Vascular smooth muscle cells

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA SMOOTH MUSCLE ACTIN; ATORVASTATIN; MYOCARDIN; ACTIN; ACTIN BINDING PROTEIN; AMIDE; ENZYME INHIBITOR; GERANYLGERANYL PYROPHOSPHATE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID PHOSPHATE; MEVALONIC ACID; MUSCLE PROTEIN; NUCLEAR PROTEIN; POTASSIUM CHLORIDE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSACTIVATOR PROTEIN; TRANSGELIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; TREATMENT RESPONSE; ANIMAL; AORTA; C57BL MOUSE; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IN VITRO STUDY; MALE; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WESTERN BLOTTING;

ACTINS; AMIDES; ANIMALS; AORTA; BLOTTING, WESTERN; CELL LINE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEVALONIC ACID; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NUCLEAR PROTEINS; POLYISOPRENYL PHOSPHATES; POTASSIUM CHLORIDE; PYRIDINES; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; TRANS-ACTIVATORS; VASOCONSTRICTION;

EID: 84865825307     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.195644     Document Type: Article

References (34)

1. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005;96:24F-33F.
2. Van Aelst L, D'Souza-Schorey C. Rho gtpases and signaling networks. Genes Dev. 1997;11:2295-2322.
3. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14:37-44.
4. Hall A. Rho gtpases and the actin cytoskeleton. Science. 1998;279:509-514.
5. Li M, Liu Y, Dutt P, Fanburg BL, Toksoz D. Inhibition of serotonininduced mitogenesis, migration, and erk mapk nuclear translocation in vascular smooth muscle cells by atorvastatin. Am J Physiol Lung Cell Mol Physiol. 2007;293:L463-L471.
6. Chapman RH, Petrilla AA, Berman L, Benner JS, Tang SS. Are high-risk hypertensive patients being prescribed concomitant statin therapy? A retrospective cohort study. Am J Cardiovasc Drugs. 2009;9:299-308.
7. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
8. Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, Kaibuchi K, Ito M. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem. 1997;272:12257-12260.
9. Rattan S. 3-Hydroxymethyl coenzyme a reductase inhibition attenuates spontaneous smooth muscle tone via rhoa/rock pathway regulated by rhoa prenylation. Am J Physiol Gastrointest Liver Physiol. 2010;298:G962-G969.
10. Lagna G, Ku MM, Nguyen PH, Neuman NA, Davis BN, Hata A. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. J Biol Chem. 2007;282:37244-37255.
11. 2+ channels modulate expression of smooth muscle differentiation marker genes via a rho kinase/myocardin/srf-dependent mechanism. Circ Res. 2004;95:406-414.
12. Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, Small E, Krieg PA, Olson EN. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell. 2001;105:851-862.
13. Li S, Wang DZ, Wang Z, Richardson JA, Olson EN. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc Natl Acad Sci USA. 2003;100:9366-9370.
14. Wang Z, Wang DZ, Pipes GC, Olson EN. Myocardin is a master regulator of smooth muscle gene expression. Proc Natl Acad Sci USA. 2003;100:7129-7134.
15. Atorvastatin: a new lipid-lowering drug. Med Lett Drugs Ther. 1997;39:29-31.
16. Fibbi B, Morelli A, Marini M, Zhang XH, Mancina R, Vignozzi L, Filippi S, Chavalmane A, Silvestrini E, Colli E, Adorini L, Vannelli GB, Maggi M. Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the rhoa/rock pathway. J Androl. 2008;29:70-84.
17. Long X, Bell RD, Gerthoffer WT, Zlokovic BV, Miano JM. Myocardin is sufficient for a smooth muscle-like contractile phenotype. Arterioscler Thromb Vasc Biol. 2008;28:1505-1510.
18. Jeon ES, Park WS, Lee MJ, Kim YM, Han J, Kim JH. A rho kinase/myocardin-related transcription factor-a-dependent mechanism underlies the sphingosylphosphorylcholine-induced differentiation of mesenchymal stem cells into contractile smooth muscle cells. Circ Res. 2008;103:635-642.
19. 2+ sensitivity of smooth muscle and nonmuscle myosin II: Modulated by g proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325-1358.
20. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A. Involvement of rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001;15:1062-1064.
21. Yang L, Gao Y-J, Lee RMKW. The effects of quinapril and atorvastatin on artery structure and function in adult spontaneously hypertensive rats. Eur J Pharmacol. 2005;518:145-151.
22. Noma K, Oyama N, Liao JK. Physiological role of rocks in the cardiovascular system. Am J Physiol Cell Physiol. 2006;290:C661-C668.
23. Zhou Q, Liao JK. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des. 2009;15:3108-3115.
24. Corsini A, Ferri N, Cortellaro M. Are pleiotropic effects of statins real? Vasc Health Risk Manag. 2007;3:611-613.
25. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003;5:372-378.
26. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.
27. Zhou Q, Liao JK. Pleiotropic effects of statins: basic research and clinical perspectives. Circ J. 2010;74:818-826.
28. Ye Y, Hu SJ, Li L. Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the rhoa/rho kinase pathway. FEBS Lett. 2009;583:2997-3003.
29. Derk CT, Jimenez SA. Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev. 2006;5:25-32.
30. Katayama M, Kawata M, Yoshida Y, Horiuchi H, Yamamoto T, Matsuura Y, Takai Y. The posttranslationally modified c-terminal structure of bovine aortic smooth muscle rhoa p21. J Biol Chem. 1991;266:12639-12645.
31. Adamson P, Marshall CJ, Hall A, Tilbrook PA. Post-translational modifications of p21rho proteins. J Biol Chem. 1992;267:20033-20038.
32. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241-269.
33. Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, Sanchez-Lopez E, Rodriguez-Vita J, Esteban V, Carvajal G, Plaza JJ, Egido J, Ruiz-Ortega M. HMG-CoA reductase inhibitors decrease angiotensin ii-induced vascular fibrosis: role of rhoa/rock and MAPK pathways. Hypertension. 2007;50:377-383.
34. Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, Isaka N, Hartshorne DJ, Nakano T. Activation of rhoa and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res. 2003;92:411-418.